Pill Makes Fasting Easier
Israeli Arabs may soon make your Yom Kippur fast easier.
It’s often said that Jews and Muslims have a lot in common when it comes to religious observance, and that’s rarely highlighted better than when it comes to fasting. Both religions require full-on fasting several times a year.
Now there’s a theory that a drug called etoricoxib (commercial name Arcoxia), if taken before a fast day, reduces the occurrence of migraines and headaches. Before Yom Kippur, doctors at Jerusalem’s Shaare Zedek Medical Center gave 211 patients pills to take — some were placebos, others were etoricoxib. Those who took the real thing — which conveniently remains active in the body for 22 hours — reported an easier fast.
The same researchers are working with Muslims who are fasting through Ramadan to continue their research, and if all goes well, they may just find a cure to fast-related migraines. On their recruitment website, they present the participation in the research as a religious virtue, as it will test whether the drug will “decrease the incidence of people breaking their fast.” You can see more on the experiment in this piece in the Jerusalem Post.
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.
Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.
Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly.
— Rachel Fishman Feddersen, Publisher and CEO
Join our mission to tell the Jewish story fully and fairly.
